May 31, 2018

Getting Advanced Stage Cancer Patients on TRK with Targeted Therapy

Response to larotrectinib “almost miraculous”

infusion_650x450

Up to 80 percent of patients with stage 4 metastatic cancers carrying tropomyosin receptor kinase (TRK) fusions who have exhausted most standard treatment options respond to larotrectinib, a new receptor inhibitor in development, according to multicenter, nationwide studies.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“It’s almost miraculous,” says study author Davendra Sohal, MD, MPH, staff in the Department of Hematology and Medical Oncology at Cleveland Clinic, one of the sites for the phase 1/2 clinical trials published in The New England Journal of Medicine.

“Generally fewer than 10 percent of these patients respond to additional attempts at chemotherapy or other standard treatments,” he says. However, results reveal that larotrectinib demonstrated efficacy regardless of patient age or type of solid tumor.

What the 55 patients in the studies had in common were TRK fusion genetic alterations. Unlike a traditional genetic mutation where an oncogene switches into overdrive, in this case one gene in a tumor combines with another, causing uncontrolled activity of TRK gene. “That leads to uncontrolled growth of the tumor, one that is very resistant to standard therapies,” Dr. Sohal says.

Larotrectinib is able to target this genetic alteration in a majority of patients. Although TRK fusions only arise in about 1 in 100 tumors, they are “surprisingly responsive to therapy if one can find the fusion and find the drug [to target it],” he adds. In this case, Loxo Oncology is developing the oral inhibitor larotrectinib (LOXO-101), which “essentially stops that fusion. It shuts it down.”

Patients in the clinical trials ranged from 4 months to 76 years old. They presented with 17 different types of TRK fusion-positive cancers. Independent reviewers and investigators agreed on overall clinical response, 75 and 80 percent, respectively.

Advertisement

The research also revealed a durable response, with 71 percent of initial responses continuing at one year. Fifty-five percent of the participants remained progression-free from cancer.

After a median follow-up of more than nine months, 86 percent of the responders (38 of 44 participants) continued treatment or underwent surgery intended to be curative.

Most adverse events were grade 1 in severity. Grade 3 or 4 treatment-related adverse events were reported in less than 5 percent of participants, and no patients discontinued treatment because of these adverse events.

Genomics-driven expertise

The current study is one of many made possible by a strong clinical genomics program at Cleveland Clinic. Many tumors undergo testing for genomic alterations, which get reviewed by the Genomics Tumor Board, a regular meeting with various oncologists, translational scientists, pathologists and genetic counselors.

Experts then alert each patient’s physician to recommended, individualized treatment options, as well as to clinical trials for which the patient might be an appropriate candidate. “It seems to work very well,” Dr. Sohal says. We offer tumor genomic profiling to every patient who is eligible.”

Advertisement

Many cancer patients need to consider the financial implications of cutting-edge therapies as well, Dr. Sohal says. “We have clinical studies and can treat patients while deferring their out-of-pocket costs. Even when patients have to pay for genomic testing, we have a very strong financial assistance program to minimize their out-of-pocket cost.”

The clinical trials allow patients unique access to promising agents in development. “And sometimes we hit the jackpot, like in this case.”

Photo Credit: Russell Lee

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad